Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Hepatology (Baltimore, Md.)|December 22, 2000
The role of liver biopsy in chronic hepatitis CS Saadeh, G Cammell, W D Carey, et al.
Journal of Viral Hepatitis|February 18, 2014
Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatmentJ Aggarwal, M Vera-Llonch, M Donepudi, et al.
Molekuliarnaia Biologiia|May 31, 2012
[Selection of reliable reference genes for qRT-PCR analysis in human non-cancerous gastric tissue]A Birerdinc, R Mehta, R Alhussain, et al.
Alimentary Pharmacology & Therapeutics|June 4, 2013
Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE studyM Vera-Llonch, M Martin, J Aggarwal, et al.
Journal of Viral Hepatitis|March 9, 2017
Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United StatesK Young, B Liu, T Bhuket, et al.
Journal of Viral Hepatitis|February 25, 2018
Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in EuropeP Cacoub, P Buggisch, J A Carrión, et al.
Alimentary Pharmacology & Therapeutics|April 18, 2018
Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO networkS L Flamm, B Bacon, M P Curry, et al.
Journal of Viral Hepatitis|October 21, 2015
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countriesZ Younossi, A Brown, M Buti, et al.
The American Journal of Gastroenterology|June 11, 1999
Immunogenicity of hepatitis A vaccine in decompensated liver diseaseJ A Dumot, D S Barnes, Z Younossi, et al.
Alimentary Pharmacology & Therapeutics|July 11, 2017
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patientsM P Curry, E B Tapper, B Bacon, et al.
Pageof 2